Monday Afternoon Session: Ion Mobility Structures in Honor of Mike Bower's 75th Birthday
This Monday afternoon session, MOC, will be presided over by Gert Von Helden of Fritz-Haber University. The session will run from 2:30?4:30 p.m. in room 309-310.
This Monday afternoon session, MOC, will be presided over by Gert Von Helden of Fritz-Haber University. The session will run from 2:30–4:30 p.m. in room 309-310.
The first talk in this session will be given by Edwin De Pauw of the Mass spectrometry laboratory at the University of Liege in Liege, Belgium. De Pauw’s talk is titled “Are Disulfide Bridges Opened by ETD?”
Kyle L. Fort of Texas A&M University in College Station, Texas, will present next. His talk is titled “Substance P from Solution to the Gas Phase: Factors that Stabilize Kinetically Trapped Conformations.”
The next talk is titled “Utilizing High Throughput IMS-MS Measurements to Analyze Small Molecules and Their Noncovalent Interactions with Macromolecular Complexes.” Erin Baker of Pacific Northwest National Laboratory in Richland, Washington, will present this talk.
Samuel J. Allen of the University of Washington in Seattle, Washington, will present next. Allen’s talk is titled “Supercharging of Native Protein Complexes: Effects of Polarity and Evidence for Multiple Mechanisms.”
“Ion Mobility and Solution Studies Show Specific Competitive Binding of Homo- and Hetero-multimer Receptor:Protein: Carbohydrate Binding” will be presented next by Julie A. Leary of UC Davis, California.
The final presentation in this session will be given be Christian Bleiholder of Florida State University in Tallahassee, Florida. Bleiholder’s talk is titled “Projected Superposition Approximation: A Novel Parameter Set for Prediction of Cross Sections in Nitrogen as a Drift Gas.”
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
